- SourceMouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Bevacizumab F(ab")2.
- IsotypeIgG1/kappa
- SpecificityRecognizes Bevacizumab specifically, no cross reactivity with other humanized antibodies.
- Purity
>95% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 years under sterile conditions after reconstitution.
Anti-Bevacizumab Antibodies (recommended for neutralizing assay) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 0.05 µg/mL, add increasing concentrations of Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (Cat. No. BEB-Y12, 10% human serum) and then add biotinylated bevacizumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 62 ng/mL.
Demonstration of the specificity of Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (Cat. No. BEB-Y12) to the bevacizumab.
Measured by its neutrlizing ability in a functional ELISA.Immobilized bevacizumab at 2 μg/mL (100 μL/well) can bind pre-mixed Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (Cat. No. BEB-Y12) and Biotinylated Human VEGF 165 (Cat. No. VE5-H82Q0) with a inhibition rate of 96%.
Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (mouse IgG1, Cat. No. BEB-Y12) captured on CM5 chip via anti-mouse antibodies surface, can bind human bevacizumab with an affinity constant of 0.08 nM.
- BackgroundA recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
生物工程的应用领域非常广泛，包括农业、工业、医学、药物学、能源、环保、冶金、化工原料等。它必将对人类社会的政治、经济、军事和生活等方面产生巨大的影响，为世界面临的资源、环境和人类健康等问题的解决提供美好的前景。展开
红细胞压积，是指红细胞占血液体积的比例，您仅仅是比参考范围略低，同时红细胞数量，和血红蛋白并没有下降，这可能是血液有所稀释所致。
白细胞计数3.9，正常的话 4-10之间，你仅仅是比参考范围略下降一丁点，本身并无意义，参考范围是大致的。而且血液还可能存在稀释可能性
中性粒细胞绝对值和百分比略低一点，同时淋巴细胞百分比略有上升，那这本身就只是略高一点点，而一般比如感冒以后，也往往可以升高，其他的红细胞分布宽度等是派生指标，没大意义的。
总之单单看这一个血常规检验，本身没有什么大的异常发现，当然也可以稍后复查，比如过2周以后复查
我是厉清，更多医疗知识，请看 厉清就是我 的新浪博客
生物工程包括五大工程，即遗传工程(基因工程)、细胞工程、微生物工程(发酵工程)、酶工程(生化工程)和生物反应器工程。在这五大领域中，前两者作用是将常规菌(或动植物细胞株)作为特定遗传物质受体，使它们获得外来基因，成为能表达超远缘性状的新物种——“工程菌”或“工程细胞株”。后三者的作用则是这一有巨大潜在价值的新物种创造良好的生长与繁殖条件，进行大规模的培养，以充分发挥其内在潜力，为人们提供巨大的经济效益 和社会效益。
生物工程的应用领域非常广泛，包括农业、工业、医学、药物学、能源、环保、冶金、化工原料等。它必将对人类社会的政治、经济、军事和生活等方面产生巨大的影响，为世界面临的资源、环境和人类健康等问题的解决提供美好的前景。展开
如题，求助。做肝癌细胞侵袭、迁移实验，用哪种细胞株比较好？
看到之前的一个朋友也发了IBC会议的PPT内容，不过好像没有这个PPT（不确定，要是重复了请见谅）。
因为会议上投影的问题，当时有些内容贾老师没介绍太多。不过内容相当不错，主要是国内比较缺乏这方面的信息和经验。可以算得上是干货吧，不过里面主要是一些规则性或方向性的内容，需要具体细节，只能花钱请她做顾问了。
AudreyJia是美籍华人，在FDA做CMCReviewer之前也一直是从事细胞开发及细胞培养的工作。她应该也是目前唯一一个生物大分子部门中，唯一从FDA离职出来从事顾问工作的。可能很多国内单抗药企大佬都认识她，可能很多园子里面的人也见过她了。
谁能赏几个积分啊？新人，没积分，一些东西想看或者下载都不行。
版主jackieustc留言:
感谢分享，鼓励新人，我给你打赏，多交流自然有收获！
Monoclonality_JIA1.pdf(952.57k)
